期刊文献+

顶空气相色谱法测定卡巴他赛中有机溶剂的残留量 被引量:2

Determination of residual solvents in cabazitaxel by headspace gas chromatography
原文传递
导出
摘要 目的 建立顶空气相色谱法测定卡巴他赛中甲醇、乙醇、丙酮、二氯甲烷和正己烷共5种有机溶剂的残留量。方法采用顶空气相色谱法,氢火焰离子化检测器;载气为氮气,流速为2.0 m L·min-1;色谱柱为DB-624毛细管柱(30 m×530μm,3μm);采用柱温50℃保持7 min,以50℃·min-1的速率升温至220℃,保持3 min;进样口温度为200℃,检测器温度为250℃;分流进样,分流比为5∶1;顶空平衡温度为100℃,顶空平衡时间为20 min;顶空定量环体积为1 m L。以外标法用峰面积计算残留溶剂的含量。结果 甲醇、乙醇、丙酮、二氯甲烷和正己烷的线性关系良好(r=0.997 8~0.999 5),平均回收率为94.0%~99.1%,检测限分别为0.67、0.64、0.23、0.94和0.03 mg·L-1。结论 本方法可用于卡巴他赛中残留溶剂的检查。 Objective To establish a method for determination of five kinds of residual solvents in cabazitaxel by headspace gas chromatography. Methods The residual solvents were separated on DB-624 (30 m × 530 μm,3 μm)capillary chromatography column equipped with FID detector. The carries gas was nitrogen with the flow rate of 2. 0 mL. min - 1. The initial temperature of column was set at 50 ℃ and maintained for 7 min, and then followed by raising the temperature to 220 ℃ with a rate of 50 ℃. min -1 and maintaining for 3 min. The inlet temperature was 200 ℃ and the FID detector temperature was 250 ℃. Split ratio was 5: 1. The temperature of the headspace oven was heated to 100 ℃ and lasted for 20 rain. The injection volume was 1.0 mL. The content of residual solvents was calculated by using external standard method. Results There was a good linear relationship in the experimental concentrations of five residual solvents ( r =0. 997 8 -0. 999 5). The average recovery ranged from 94. 0% to 99. 1%. The limit of detection was 0. 67,0. 64,0. 23,0. 94, and 0. 03 mg. L - 1 respectively. Conclusions The method can be used for detection of residual solvents in cabazitaxel.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2016年第9期718-722,共5页 Journal of Shenyang Pharmaceutical University
关键词 卡巴他赛 顶空气相色谱法 残留溶剂 cabazitaxel headspace gas chromatography residual solvent
  • 相关文献

参考文献9

二级参考文献32

  • 1单鸣秋,张发成,毛志英.多西他赛中有机溶剂残留量的毛细管气相色谱测定[J].中国医药工业杂志,2004,35(12):751-752. 被引量:2
  • 2国家药品标准[S].WS1-(X-129)-2005Z“多西他赛”.
  • 3国家药品标准[S].YBH22162004“多西他赛”.
  • 4JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009 [J]. CA Cancer JClin, 2009, 59(4): 225 -249.
  • 5PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004, 351(15) : 1513 -1520.
  • 6BERRY DL, MOINPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone[ J]. J Clin Oncol, 2006, 24(18) : 2828 -2835.
  • 7Jevtana [ EB/OL ].[ 2010 - 11 - 02 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2010/2010231bl, pdf.
  • 8Sanofi-aventis. XRP6258 investigator's brochure[ M]. Antony (France) : Sanofi-aventis,2000.
  • 9ATTARD G, GREYSTOKE A, KAYE S, et al. Update on tubulin binding agents [ J ]. Pathol Biol( Paris), 2006, 54 ( 2 ) : 72 - 84.
  • 10PIVOTI X, KORALEWSKI P, HIDALGO JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008, 19(9) : 1547 -1552.

共引文献71

同被引文献21

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部